The U.S. Pharmacopeia released reference standards and analytical reference materials (ARMs) to help manufacturers test GLP‑1 peptide therapeutics for product‑ and process‑related impurities. USP framed the resources as a response to rapid market growth, supply strain and a rise in fraudulent or counterfeit GLP‑1 products cited by EMA and FDA. The materials aim to support method development, validation and cross‑lab comparability. Manufacturers and contract labs now have access to characterized standards to improve assay accuracy; the move also underscores regulatory and supply‑chain pressures facing peptide therapeutics as demand surges.